Compare BBIO & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBIO | BTX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 756.3M |
| IPO Year | 2019 | N/A |
| Metric | BBIO | BTX |
|---|---|---|
| Price | $75.10 | $6.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 21 | 0 |
| Target Price | ★ $76.24 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 924.1K |
| Earning Date | 10-29-2025 | 11-01-2025 |
| Dividend Yield | N/A | ★ 12.63% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $353,780,000.00 | N/A |
| Revenue This Year | $128.44 | N/A |
| Revenue Next Year | $76.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 62.46 | N/A |
| 52 Week Low | $25.34 | $5.10 |
| 52 Week High | $77.20 | $8.31 |
| Indicator | BBIO | BTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.34 | 52.58 |
| Support Level | $73.48 | $6.35 |
| Resistance Level | $76.51 | $6.84 |
| Average True Range (ATR) | 2.49 | 0.13 |
| MACD | -0.27 | -0.01 |
| Stochastic Oscillator | 78.39 | 68.74 |
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.